Fatigue in breast cancer survivors two to five years post diagnosis: a HEAL Study report

Meeske, Kathleen; Smith, Ashley Wilder; Alfano, Catherine M.; McGregor, Bonnie A.; McTiernan, Anne; Baumgartner, Kathy B.; Malone, Kathleen E.; Reeve, Bryce B.; Ballard‐Barbash, Rachel; Bernstein, Leslie

doi:10.1007/s11136-007-9215-3

Cited by 131 publications

(142 citation statements)

References 53 publications

(72 reference statements)

Supporting

Mentioning

116

Contrasting

Unclassified

Order By: Relevance

“…First, antidepressant use in our cancer study population (27.7%) was similar to antidepressant use in previous studies (10% to 34%) [11,239,[255][256][257][258][259][260][261][262]. Specifically, in breast cancer patients, 34.4% used antidepressants, which is consistent with the maximum reported percentage of breast cancer patients using antidepressants in previous studies (11% to 34%) [11,239,[255][256][257][258][259][260][261].…”

Section: Strengthssupporting

confidence: 88%

“…Another study found antidepressants were self-reported in 27% of breast cancer patients; this percentage increased to 32% in patients with lymphedema [259]. At a 2-year interview, 15% of breast cancer patients reported taking an antidepressant [260], while another 2-year study found 19.2% of breast cancer patients were prescribed antidepressants [256]. Using a prescription database, among women taking tamoxifen who were older than 66, 30.6% were prescribed at least one SSRI or venlafaxine [261].…”

Section: Antidepressant Usementioning

confidence: 99%

“…A waiting room sample of breast cancer patients revealed that 34% of the population was prescribed antidepressants [255]. Overall, rates of antidepressant use in breast cancer population ranged from 11% to 34% [11,239,[255][256][257][258][259][260][261]. Among patients diagnosed with melanoma, rates ranged from 10.1% to 24.9% [262], and 15% of NHL patients used tricyclic antidepressants [263].…”

Section: Antidepressant Usementioning

confidence: 99%

See 2 more Smart Citations

Antidepressant use and risk of central nervous system metastasis

et al. 2016

View full text Add to dashboard Cite

Section: Strengthssupporting

confidence: 88%

Section: Antidepressant Usementioning

confidence: 99%

Section: Antidepressant Usementioning

confidence: 99%

See 1 more Smart Citation

Antidepressant use and risk of central nervous system metastasis

et al. 2016

View full text Add to dashboard Cite

“…Moreover, previous studies have confirmed that breast cancer survivors with increased fatigue rated their quality of life at a lower level [12][13][14]16 . On the other hand, assessing fatigue in cancer survivors is a challenge since fatigue is also a common complaint with some level of fatigue reported by the general population 17,18 .…”

Section: Introductionmentioning

confidence: 75%

“…Many studies suggest that fatigue is a common problem experienced by female survivors of breast cancer 6,[9][10][11][12][13][14][15] . Moreover, previous studies have confirmed that breast cancer survivors with increased fatigue rated their quality of life at a lower level [12][13][14]16 .…”

Section: Introductionmentioning

confidence: 99%

Fatigue and quality of life in breast cancer survivors: a comparative study

Kluthcovsky¹,

Urbanetz²

2015

Rev. Bras. Ginecol. Obstet.

View full text Add to dashboard Cite

PURPOSE: To assess fatigue and quality of life in disease-free breast cancer survivors in relation to a sample of age-matched women with no cancer history and to explore the relationship between fatigue and quality of life. METHODS: A cross-sectional study was conducted in a sample of 202 consecutive disease-free Brazilian breast cancer survivors, all of whom had completed treatment, treated at 2 large hospitals. The patients were compared to age-matched women with no cancer history attending a primary health care center. The Piper Fatigue Scale-Revised and the World Health Organization Quality of Life Instrument (WHOQOL-BREF) were used to measure the fatigue and quality of life, respectively. Socio-demographic and clinical variables were also obtained. The χ 2 test, generalized linear model, and Spearman correlation coefficient were used for statistical purposes. The adopted level of significance was 5%. RESULTS: Breast cancer survivors experienced significantly greater total and subscale fatigue scores than comparison group (all p-values<0.05). In addition, survivors reported a poorer quality of life in physical (p=0.002), psychological (p=0.03), and social relationships (p=0.03) domains than comparison group. No difference was found for the environmental domain (p=0.08) for both groups. For survivors of breast cancer and for comparison group, the total and subscale fatigue scores were related to lower quality of life (all p-values<0.01). CONCLUSION: The findings of this study highlight the importance of assessing fatigue and quality of life in breast cancer survivors. ResumoOBJETIVO: Avaliar a fadiga e a qualidade de vida de sobreviventes de câncer de mama, livres da doença, em relação a uma amostra de mulheres da mesma idade, sem histórico de câncer, e explorar a relação entre fadiga e qualidade de vida. MÉTODOS: Estudo transversal realizado com uma amostra consecutiva de 202 pacientes brasileiras, sobreviventes de câncer de mama e livres da doença, que haviam completado o tratamento em 2 grandes hospitais. As pacientes foram comparadas com mulheres da mesma idade, sem história de câncer, acompanhadas em uma Unidade Básica de Saúde. A Escala de Fadiga de Piper-Revisada e o World Health Organization Quality of Life Instrument (WHOQOL-BREF) foram usados para avaliar a fadiga e a qualidade de vida, respectivamente. Dados sociodemográficos e clínicos também foram obtidos. O teste do χ 2 , modelo linear generalizado e coeficiente de correlação de Spearman foram utilizados para fins estatísticos. Foi adotado o nível de significância de 5%. RESULTADOS: As sobreviventes de câncer de mama apresentaram significativamente maiores escores de fadiga total e das subescalas do que o grupo controle (todos os valores de p<0,05). Além disso, as sobreviventes relataram pior qualidade de vida nos domínios físico (p=0,002), psicológico (p=0,03) e relações sociais (p=0,03) do que o grupo controle. Nenhuma diferença foi encontrada para o domínio ambiental (p=0,08) entre os 2 grupos. Para as sobreviventes de câncer de mama...

show abstract

Overexpression of toll‐like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: Toll‐like receptor expression in early and longstanding arthritis

Ospelt

Brentano

Rengel

et al. 2008

Arthritis & Rheumatism

297

244

View full text Add to dashboard Cite

Objective. To analyze the expression, regulation, and biologic relevance of Toll-like receptors (TLRs) 1-10 in synovial and skin fibroblasts and to determine the expression levels of TLRs 2, 3, and 4 in synovial tissues from patients with early rheumatoid arthritis (RA), longstanding RA, and osteoarthritis (OA).Methods. Expression of TLRs 1-10 in RA synovial fibroblasts (RASFs), OASFs, and skin fibroblasts was analyzed by real-time polymerase chain reaction (PCR).

show abstract

Fatigue in breast cancer survivors two to five years post diagnosis: a HEAL Study report

Abstract: This study provides further support for the conclusion that a significant proportion of breast cancer survivors experience fatigue that compromises HRQOL two to five years post-diagnosis.

Cited by 131 publications

References 53 publications

Antidepressant use and risk of central nervous system metastasis

Antidepressant use and risk of central nervous system metastasis

Fatigue and quality of life in breast cancer survivors: a comparative study

Overexpression of toll‐like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: Toll‐like receptor expression in early and longstanding arthritis

Contact Info

Product

Resources

About